93
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Primary Sites of Uveal Melanoma Associated with Distinct Survival Outcomes and Clinicopathological Features: A SEER Population-Based Study of 4359 Cases

, , &
Pages 5221-5232 | Published online: 04 Sep 2021

References

  • Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881–1885. doi:10.1016/j.ophtha.2011.01.040
  • Jang BS, Chang JH, Oh S, Lim YJ, Kim IH. Chirurgie vs. strahlentherapie bei patienten mit uveamelanom: analyse der SEER-datenbank mithilfe von propensity-score-matching und -gewichtung. Strahlentherapie und Onkologie. 2017;193(11):931–942. doi:10.1007/s00066-017-1203-0
  • Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973–1997. Ophthalmology. 2003;110(5):962–965. doi:10.1016/s0161-6420(03)00077-0
  • Andreoli MT, Mieler WF, Leiderman YI. Epidemiological trends in uveal melanoma. Br J Ophthalmol. 2015;99(11):1550–1553. doi:10.1136/bjophthalmol-2015-306810
  • Zloto O, Pe’er J, Frenkel S. Gender differences in clinical presentation and prognosis of uveal melanoma. Invest Ophthalmol Vis Sci. 2013;54(1):652–656. doi:10.1167/iovs.12-10365
  • Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB. Variates of survival in metastatic uveal melanoma. J Clin Oncol. 2005;23(31):8076–8080. doi:10.1200/jco.2005.02.6534
  • Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8033 cases. Retina. 2012;32(7):1363–1372. doi:10.1097/IAE.0b013e31824d09a8
  • Augsburger JJ, Gamel JW, Lauritzen K, Brady LW. Cobalt-60 plaque radiotherapy vs enucleation for posterior uveal melanoma. Am J Ophthalmol. 1990;109(5):585–592. doi:10.1016/S0002-9394(14)70691-9
  • Augsburger JJ, Schneider S, Freire J, Brady LW. Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroidal melanomas: results in patients treated between 1980 and 1987. Graefes Arch Clin Exp Ophthalmol. 1999;237(7):558–567. doi:10.1007/s004170050279
  • Seddon JM, Gragoudas ES, Egan KM, et al. Relative survival rates after alternative therapies for uveal melanoma. Ophthalmology. 1990;97(6):769–777. doi:10.1016/S0161-6420(90)32512-5
  • Querques G, Bux AV, Iaculli C, Delle Noci N. Local resection versus combined local resection and plaque radiotherapy in the treatment of choroidal melanoma. Eur J Ophthalmol. 2010;20(1):194–200. doi:10.1177/112067211002000127
  • Shields CL, Sioufi K, Robbins JS, et al. Large uveal melanoma (>/=10 mm thickness): clinical features and millimeter-by-millimeter risk of metastasis in 1311 cases. The 2018 Albert E. Finley lecture. Retina. 2018;38(10):2010–2022. doi:10.1097/IAE.0000000000002144
  • Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol. 2001;119(7):969–982. doi:10.1001/archopht.119.7.969
  • Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127(8):989–998. doi:10.1001/archophthalmol.2009.208
  • Damato B, Coupland SE. A reappraisal of the significance of largest basal diameter of posterior uveal melanoma. Eye. 2009;23(12):2152–2160. doi:10.1038/eye.2009.235-cme
  • McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol. 1982;13(2):123–132. doi:10.1016/s0046-8177(82)80116-0
  • Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996;347(9010):1222–1225. doi:10.1016/S0140-6736(96)90736-9
  • Damato B, Duke C, Coupland SE, et al. Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology. 2007;114(10):1925–1931. doi:10.1016/j.ophtha.2007.06.012
  • Rummelt V, Folberg R, Woolson RF, Hwang T, Pe’er J. Relation between the microcirculation architecture and the aggressive behavior of ciliary body melanomas. Ophthalmology. 1995;102(5):844–851. doi:10.1016/S0161-6420(95)30947-5
  • Shields CL, Kaliki S, Shah SU, Luo W, Furuta M, Shields JA. Iris melanoma: features and prognosis in 317 children and adults. J AAPOS. 2012;16(1):10–16. doi:10.1016/j.jaapos.2011.10.012
  • Li W, Gragoudas ES, Egan KM. Metastatic melanoma death rates by anatomic site after proton beam irradiation for uveal melanoma. Arch Ophthalmol. 2000;118(8):1066–1070. doi:10.1001/archopht.118.8.1066
  • Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye. 2017;31(2):241–257. doi:10.1038/eye.2016.275
  • Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11):4651–4659. doi:10.1167/iovs.03-0538
  • Bergman L, Seregard S, Nilsson B, Lundell G, Ringborg U, Ragnarsson-Olding B. Uveal melanoma survival in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci. 2003;44(8):3282–3287. doi:10.1167/iovs.03-0081
  • Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells. Br J Ophthalmol. 1978;62(6):420–425. doi:10.1136/bjo.62.6.420
  • Zimmerman LE, McLean IW. An evaluation of enucleation in the management of uveal melanomas. Am J Ophthalmol. 1979;87(6):741–760. doi:10.1016/0002-9394(79)90348-9
  • Affeldt JC, Minckler DS, Azen SP, Yeh L. Prognosis in uveal melanoma with extrascleral extension. Arch Ophthalmol. 1980;98(11):1975–1979. doi:10.1001/archopht.1980.01020040827006